Baxter International Stock News

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To pick candidates, I use different screens every month that focus on various as

KBH, BAX, F, EGO, and AXS have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

BAX, F, and WBS made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 18, 2022

BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022

We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.

AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Baxter International CEO José Almeida said the medical supply maker has seen some shortages lately as the surge of Omicron patients has led to a spike in demand for certain products.

BOSTON , Jan. 10, 2022 /PRNewswire/ -- Medically Home today announced a new, $110 million round of funding from strategic investors including Baxter International Inc., Global Medical Response (GMR) and Cardinal Health who will each have representation on the company''s Board. Cardinal Health, Mayo Clinic and Kaiser Permanente are providing additional capital on top of their previous investments, demonstrating confidence in the growing expansion of the model nationwide. Medically Home Announces a $110 Million Investment The Medically Home model unlocks patients'' homes as safe alternative sites to receive high and lower acuity care across the care continuum in the comfort and convenience of their homes. This capability is designed to increase health system capacity and resiliency, while meeting the needs and wants of patients, who often prefer to be cared for at home or in a homelike setting. More than 7,000 patients have been treated using the Medically Home platform and ecosystem, as delivered by health systems across the country and utilization is expanding rapidly.

Baxter International Inc. (BAX) shares closed today at 1.6% below its 52 week high of $88.91, giving the company a market cap of $43B. The stock is currently up 1.9% year-to-date, up 8.5% over the past 12 months, and up 103.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -279.4% The company's stock price performance over the past 12 months beats the peer average by 63.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Baxter International Inc. (BAX) shares closed today at 1.6% below its 52 week high of $88.91, giving the company a market cap of $43B. The stock is currently up 1.9% year-to-date, up 8.8% over the past 12 months, and up 103.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 0.1% higher than its 5-day moving average, 2.6% higher than its 20-day moving average, and 7.8% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -353.3% The company's stock price performance over the past 12 months beats the peer average by 46.8% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2021 financial results on Thursday, February